CytomX Therapeutics will eliminate 40% of its workforce, a move that jolts a Bay Area biotech sector already reeling from repeated downsizings. The South San Francisco cancer research firm confirmed 45 local job cuts plus five remote positions in a January 6 regulatory filing.
The restructuring arrives at a pivotal moment for the company. Executives explained the reductions will redirect capital toward active clinical programs while creating breathing room in the budget. Most departing employees work in administrative roles and early-stage research not tied to existing partnerships.
Senior leadership took a direct hit. A vice president, a senior vice president, four senior directors, and seven directors all appear on the termination list alongside research associates and more than a dozen scientists. Some workers leave January 17; others remain through March 7.
CytomX has never brought a drug to market nor completed a successful late-stage trial. Its survival hinges on three oncology drug candidates designed to target tumors while sparing healthy cells. Development partners include Amgen, Bristol Myers Squibb, and Moderna. Revenue from those alliances actually pushed the company into profitability for the quarter ending September 30.
Still, the financial runway looks precarious. The layoffs stretch available cash only into mid-2026. One promising drug candidate now sits in limbo while leadership evaluates funding options. Accumulated losses reached $710 million as of September, and the company acknowledged it needs substantial additional funding with no guarantee of securing favorable terms.
Compounding the pressure, CytomX cannot tap public markets for a fresh infusion. The firm listed on NASDAQ in 2015, hit a peak valuation above $1.2 billion in 2018, then watched its worth collapse. As of early this week, the company commanded roughly $70 million. That figure represents a 94% decline from its all-time high.
